Holen Sie sich die Stockscreener-App
3.00
3.45%
0.10
Schlusskurs vom Vortag:
$2.90
Offen:
$3
24-Stunden-Volumen:
170.32K
Relative Volume:
2.53
Marktkapitalisierung:
$1.07B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-5.7045
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
-5.96%
1M Leistung:
+0.33%
6M Leistung:
-27.36%
1J Leistung:
-35.76%
1-Tages-Spanne:
$2.945
$3.0215
1-Wochen-Bereich:
$2.86
$3.23
52-Wochen-Spanne:
$2.84
$5.10
Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.00 | 1.03B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Antibody Discovery Market to Reach USD 17.68 Billion by 2032, Driven by Rising Demand for Targeted Therapies and Advancements in AI Powered Antibody Engineering – SNS Insider - GlobeNewswire Inc.
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
Evotec shares tumble 9% as drug discovery segment weakens By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com India
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec SE Sponsored ADR Trade Ideas — NASDAQ:EVO - TradingView
8 New 4-Star Stocks - Morningstar
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):